Sanofi Stays Bullish On Synthorx IL-2 Drug, But It’s Early Days
Drug Maker Presents Initial Phase I Data At AACR
In an interview, oncology development exec Peter Adamson reiterated the company’s view that THOR-707 is best-in-class, but more data are needed to see where its efficacy stands amid the IL-2 herd.
You may also be interested in...
Strong sales of Dupixent and its range of vaccines are expected to drive Sanofi’s financial results for the first quarter of 2021, although these are likely to have been adversely affected by currency exchange rate movements. Numerous data readouts are expected in the coming months from pipeline products.
In this week's podcast version of Five Must-Know Things, hear about adenovirus vaccines and blood clots, Lilly’s new moves in genetic diseases, the efficacy debate over Chinese COVID-19 vaccines, putting a price tag on innovation, and Sanofi’s bullishness on IL-2.
Executives pointed to the IL-2 variant drug’s potential for subcutaneous administration as a key differentiator from other IL-2 variant programs.